Skip to main content
. 2020 Jan 7;19:2. doi: 10.1186/s12933-019-0979-x

Fig. 2.

Fig. 2

Comparison of the cumulative incidence of recurrent ischemic stroke between pioglitazone and non-pioglitazone groups in the propensity score matched cohort. The curves show lower risks of recurrent ischemic stroke in the pioglitazone group